Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lamberti, J. S. Articles by Dietz, M. B. Search for Related Content PubMed Citation Articles by Lamberti, J. S. Articles by Dietz, M. B. Schizophrenia Spectrum Disorders Suicide Atypical Neuroleptics Epidemiology Related Article

Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine

OBJECTIVE: This study compared the prevalence of the metabolic syndrome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matched comparison group from the National Health and Nutrition Examination Survey. METHOD: Ninety-three outpatients and a matched group of 2,701 comparison subjects were compared according to National Cholesterol Education Program criteria. Outpatient data were obtained through physical assessments, laboratory testing, and reviews of medical records. RESULTS: The prevalence of the metabolic syndrome was significantly higher among clozapine patients (53.8%) than among the comparison group (20.7%). For clozapine patients, logistic regression analysis revealed significant associations with age, body mass index, and duration of clozapine treatment. Only age and body mass index were associated with the prevalence of metabolic syndrome in both groups. CONCLUSIONS: Patients receiving clozapine are at significantly increased risk for developing the metabolic syndrome. Psychiatrists and other providers should consider performing regular physical health monitoring to prevent long-term adverse health consequences.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A58. [Full Text] [PDF]

This article has been cited by other articles:

				D. Morgan, M. Sargeant, J. Chukwuma, and G. Hughes Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations Psychiatr. Bull., May 1, 2008; 32(5): 174 - 177. [Abstract] [Full Text] [PDF]

				D. Dickinson, J. M. Gold, F. B. Dickerson, D. Medoff, and L. B. Dixon Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes Psychosomatics, April 1, 2008; 49(2): 123 - 131. [Abstract] [Full Text] [PDF]

				L. Terre Behavioral Medicine Review: Psychological Risks for Metabolic Syndrome American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 126 - 129. [Abstract] [PDF]

				W. S. Fenton and M. R. Chavez Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia Focus, January 1, 2008; 6(2): 246 - 253. [Abstract] [Full Text] [PDF]

				K. Ojala, E. Repo-Tiihonen, J. Tiihonen, and L. Niskanen Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents J Psychopharmacol, January 1, 2008; 22(1): 33 - 38. [Abstract] [PDF]

				W. V. Zhang, I. Ramzan, and M. Murray Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 770 - 777. [Abstract] [Full Text] [PDF]

				S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco Legal Fallacies of Antipsychotic Drugs J Am Acad Psychiatry Law, June 1, 2007; 35(2): 235 - 246. [Abstract] [Full Text] [PDF]

				W. S. Fenton and M. R. Chavez Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia Am J Psychiatry, October 1, 2006; 163(10): 1697 - 1704. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us